ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/gynaecological
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gynaecological
68
trial(s) found.
NCT06926075
Advanced
Phase 1
Not yet recruiting
An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06751329
Advanced
Phase 1
Recruiting
A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors (
DM002001
)
Colorectal cancer
Endometrial cancer
Ovarian cancer
Prostate cancer
NSW
2500 - Wollongong - Wollongong Hospital
NCT06738966
Advanced
Phase 1
Not yet recruiting
An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults with HR-positive, Locally Advanced or Metastatic Cancer (
BL0175-102
)
unknown drug class
Breast cancer
Endometrial cancer
Ovarian cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT06736704
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors (
SNV4818-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
Breast cancer
Endometrial cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
WA
6009 - Nedlands - Linear Clinical Research
NCT06617169
Advanced
Phase 1
Recruiting
Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers (
MNPR101-Lu-1-01
)
177Lu-anti-uPAR radioconjugate
Bladder cancer
Colorectal cancer
Gastric cancer
Lung cancer
Ovarian cancer
Pancreatic cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Breast cancer
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Urothelial carcinoma
Uterine serous carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06533059
Advanced
Phase 1
Recruiting
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation (
2618-001
)
AKT1 E17K inhibitor
Breast cancer
Endometrial cancer
Solid tumour
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06486441
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (
ASCENT-GYN-01
)
anti-Trop2 antibody-drug conjugate
Endometrial cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT06465069
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06459180
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (
2870-020
)
anti-Trop2 antibody-drug conjugate
Cervical cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06433219
Advanced
Phase 2
Recruiting
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302) (
MS201924-0002
)
ATM inhibitor
ATR inhibitor
PARP inhibitor
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06365853
Advanced
Phase 2
Recruiting
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (
IMGN853-0424
)
anti-FR-alpha antibody-drug conjugate
Ovarian cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2305 - New Lambton Heights - Newcastle Private Hospital
VIC
3168 - Clayton - Monash Medical Centre
NCT06305962
Advanced
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06278857
Curative
Phase 2
Recruiting
A Phase 2b, Open-label, Single Arm, Multicentre, Pilot Study of the Efficacy, Safety and Tolerability of Dostarlimab in Women With Early-stage MMR Deficient Endometrioid Endometrial Adenocarcinoma. (
SATELLITE
)
anti-PD-1 monoclonal antibody
Endometrial cancer
Endometrial endometrioid carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06257264
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors (
BG-68501-101
)
CDK2 inhibitor
Bladder cancer
Breast cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06238479
Advanced
Phase 1
Recruiting
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors (
EXCEED
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06188520
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (
CYCAD-1
)
CDK2 inhibitor
Breast cancer
High-grade serous ovarian cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
NA
4032 - Chermside - ICON Cancer Centre
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06132958
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095) (
TroFuse-005
)
anti-Trop2 antibody-drug conjugate
Endometrial cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06072781
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (
RAMP-301
)
FAK inhibitor
RAF/MEK clamp
Low-grade serous ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05870748
Advanced
Phase 2 / Phase 3
Recruiting
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) (
STRO-002-GM3
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
Platinum resistant ovarian cancer
Primary peritoneal serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
Breast cancer
Endometrial cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Solid tumour
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
NCT05797168
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (
FONTANA
)
anti-FR-alpha antibody-drug conjugate
Lung adenocarcinoma
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05756907
Advanced
Phase 1 / Phase 2
Recruiting
A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer (
SB221
)
IL-12 variant
anti-PD-L1 monoclonal antibody
Platinum resistant ovarian cancer
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2640 - Albury - Border Medical Oncology Research Unit
SA
5037 - Glandore - Ashford Cancer Centre
NCT05735080
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer (
INX-315-01
)
CDK2 inhibitor
Breast cancer
Cancer
Carcinoma
Ovarian cancer
Solid tumour
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05640999
Curative
Phase 2
Recruiting
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER) (
EN10
)
Radiotherapy
cancer therapy
Endometrial cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05619913
Advanced
Phase 2
Recruiting
The
EPOCH
Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma
anti-PD-1 monoclonal antibody
macrocyclic ketone analogue
Ovarian carcinosarcoma
Uterine carcinosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05611931
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (
XPORT-EC-042
)
XPO1 inhibitor
placebo
Endometrial cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)
QLD
4215 - Southport - ICON Cancer Care
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05498597
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours (
AMT-151-01
)
anti-FR-alpha antibody-drug conjugate
Adenocarcinoma
Cancer
Carcinoma
Endometrial cancer
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Lung adenocarcinoma
Ovarian cancer
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Pancreatic adenocarcinoma
Pleural mesothelioma
Solid tumour
Triple-negative breast cancer
Uterine serous carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05445778
Curative
Phase 3
Recruiting
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (
GLORIOSA
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Peritoneal cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4215 - Southport - Gold Coast University Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05216432
Advanced
Phase 1
Recruiting
A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (
RLY-2608-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
selective estrogen receptor degrader
Breast cancer
Endometrial cancer
HER2-negative breast cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT05201547
Advanced
Phase 3
Recruiting
Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting (
DOMENICA
)
anti-PD-1 monoclonal antibody
Endometrial cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05123482
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (
D6900C00001
)
anti-B7H4 antibody-drug conjugate
Biliary tract cancer
Breast cancer
Endometrial cancer
Ovarian cancer
Squamous non-small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NCT05081609
Advanced
Phase 1 / Phase 2
Recruiting
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (
IL-Believe
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
Breast cancer
Cervical cancer
Melanoma
Non-small cell lung cancer
Platinum resistant ovarian cancer
Small-cell lung cancer
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)
NCT04956640
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors (
LOXO-RAS-20001
)
KRAS G12C inhibitor
Biliary tract cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04814108
Advanced
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma (
ZN-c3-004
)
WEE1 inhibitor
Uterine serous carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04644068
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
PETRA
)
PARP1-selective inhibitor
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT04516447
Advanced
Phase 1
Recruiting
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer (
ZN-c3-002
)
WEE1 inhibitor
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04140526
Advanced
Phase 1 / Phase 2
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (
PRESERVE-001
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenoid cystic carcinoma
Breast cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT03746431
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours (
FPX-01-01
)
FPI-1175
FPI-1547
IGF1R-radionucleotide conjugate
cancer therapy
radioconjugate therapy
radiopharmaceutics
Breast cancer
Carcinoma
Cervical cancer
Endometrial cancer
HER2-negative breast cancer
Head and neck squamous cell carcinoma
Ovarian cancer
Solid tumour
Triple-negative breast cancer
Uveal melanoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
NCT03564340
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers (
R4018-ONC-1721
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,MUC16-targeting
Endometrial cancer
Fallopian tube cancer
Ovarian cancer
Primary peritoneal serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT02628067
Advanced
Phase 2
Recruiting
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) (
KEYNOTE-158
)
anti-PD-1 monoclonal antibody
Anal cancer
Biliary tract cancer
Cancer
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Endometrial cancer
Endometrial carcinoma
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Solid tumour
Thyroid cancer
Vulval cancer
NSW
2109 - North Ryde - Macquarie University Hospital
ACTRN12623000174684
Advanced
Phase 1
Recruiting
A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer (
APG2449OG101
)
ALK inhibitor,third generation
FAK/ALK/ROS1 inhibitor
FAK inhibitor
anthracycline
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12621000639820
Advanced
Phase 2
Recruiting
The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (
PARAGON-II
) .
Alpelisib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Letrozole
PI3K alpha inhibitor
Ribociclib
aromatase inhibitor
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,PI3Kalpha-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
oestrogen receptor-targeting therapy
Carcinoma
Endometrial cancer
Endometrial stromal sarcoma
Low-grade serous ovarian cancer
Ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Uterine leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2485 - Tweed Heads - The Tweed Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12621000273886
Curative
Phase 2
Recruiting
The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer -
ADELE
: a randomised phase 2 trial
anti-PD-1 monoclonal antibody
Endometrial cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12619001185156
Advanced
Phase 2
Recruiting
A Phase II signal-seeking trial targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate. (
IGNITE
)
ATR inhibitor
Adavosertib
Ceralasertib
WEE1 inhibitor
cancer therapy
cancer therapy,ATR-targeting
cancer therapy,WEE1-targeting
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06036836
Advanced
Phase 2
Active not recruiting
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010) (
4280A-010
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Cutaneous squamous cell carcinoma
Endometrial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06003231
Advanced
Phase 2
Active not recruiting
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2 (
SGNDV-005
)
anti-ERBB2 antibody-drug conjugate
Endometrial cancer
Head and neck cancer
Non-small cell lung cancer
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT05858736
Advanced
Phase 1
Active not recruiting
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study (
PRESERVE-009
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenocarcinoma
Anal cancer
Biliary tract cancer
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Fallopian tube cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Primary peritoneal serous carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05500508
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer (
AMXT1501-102
)
polyamine transport inhibitor
Breast cancer
Cancer
Central nervous system cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
H3K27M-mutant glioma
Head and neck cancer
Malignant glioma
Melanoma
Mesothelioma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Papillary thyroid cancer
Pleural mesothelioma
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
NCT05363605
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours (
FPI-1966-101
)
radioconjugate,FGFR3-targeting
Bladder cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Lung cancer
Ovarian cancer
Solid tumour
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05329545
Advanced
Phase 3
Terminated
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (
UP-NEXT
)
anti-NaPi2b antibody-drug conjugate
placebo
Fallopian tube cancer
High-grade serous ovarian cancer
Primary peritoneal serous carcinoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
NCT05317078
Advanced
Phase 1
Terminated
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
bispecific T-cell engager,CLDN6-targeting
Epithelial Ovarian Cancer
Non-squamous non-small-cell lung cancer
Solid tumour
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05257408
Advanced
Phase 3
Active not recruiting
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA) (
CORT125134-556
)
taxane
Fallopian tube cancer
Ovarian cancer
Peritoneal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4217 - Benowa - Pindara Private Hospital
NCT05252390
Advanced
Phase 1 / Phase 2
Not recruiting
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (
NUV-868-01
)
BET inhibitor
PARP inhibitor
antiandrogen,nonsteroidal,second generation
Breast cancer
Cancer
Castrate-resistant prostate cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Solid tumour
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05156892
Advanced
Phase 1
Unknown
A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer (
TICTOC
)
SMO inhibitor
selective estrogen receptor modulator
Ovarian cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT03188159
Advanced
Phase 2
Unknown
Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP) (
GY01-05-16
)
vinca alkaloid
Fallopian tube cancer
Ovarian cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (54)
Active not recruiting (4)
Terminated (4)
Not yet recruiting (3)
Unknown (2)
Not recruiting (1)
Recruitment Country and State
NSW (50)
VIC (45)
QLD (32)
SA (24)
WA (22)
NZ (7)
TAS (4)
ACT (2)
Phase
Phase 1 (25)
Phase 1 / Phase 2 (18)
Phase 2 (15)
Phase 2 / Phase 3 (1)
Phase 3 (9)
Trial Type
Advanced (63)
Curative (4)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
28%
PD-1
26%
oestrogen axis
16%
ER
12%
FR-alpha
9%
Trop2
7%
PARP
7%
VEGF
7%
CDK4
7%
ERBB2
6%
CDK2
6%
CDK6
6%
PI3Kalpha
4%
PARP1-selective
4%
WEE1
4%
NECTIN4
3%
ATR
3%
CDK4 selective
3%
FAK
3%
CTLA4
3%
ER alpha
1%
AKT
1%
TF
1%
ATM
1%
B7H3
1%
ERBB3
1%
MET
1%
BRAF
1%
CRAF
1%
MEK
1%
RAF
1%
pan-RAF
1%
CD39
1%
IL-12
1%
PD-L1
1%
XPO1
1%
B7H4
1%
TIGIT
1%
IL-2
1%
TLR7/TLR8
1%
EGFR
1%
KRAS
1%
KRAS G12C
1%
CCR8
1%
TP53
1%
TP53 Y220C
1%
MUC16
1%
ALK
1%
ROS1
1%
LAG3
1%
polyamine transport
1%
FGFR
1%
FGFR3
1%
NaPi2b
1%
CLDN6
1%
AR
1%
BET
1%
androgen axis
1%
SMO
1%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (21)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (15)
3168 - Clayton - Monash Medical Centre (14)
2050 - Camperdown - Chris O'Brien Lifehouse (11)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (11)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (9)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (9)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (9)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (9)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (9)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (8)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (8)
2109 - North Ryde - Macquarie University Hospital (7)
3199 - Frankston - Peninsula Health Frankston Hospital (7)
2031 - Randwick - Prince of Wales Hospital (7)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
5042 - Bedford Park - Flinders Medical Centre (5)
2500 - Wollongong - Wollongong Hospital (4)
6009 - Nedlands - Linear Clinical Research (4)
2170 - Liverpool - Liverpool Hospital (4)
4215 - Southport - Tasman Oncology (4)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (4)
3121 - Richmond - Epworth Freemasons Hospital (4)
3004 - Melbourne, Southbank - Alfred Health (3)
2031 - Randwick - Scientia Clinical Research Ltd (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (3)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (3)
2305 - New Lambton Heights - Newcastle Private Hospital (3)
2640 - Albury - Border Medical Oncology Research Unit (3)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (3)
7000 - Hobart - Royal Hobart Hospital (3)
6009 - Nedlands - One Clinical Research (3)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
4215 - Southport - Gold Coast University Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3002 - East Melbourne - Epworth Freemasons (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
2605 - Garran - The Canberra Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
5065 - Toorak Gardens - Burnside War Memorial Hospital (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
6150 - Murdoch - GenesisCare Murdoch (1)
4032 - Chermside - ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
5037 - Glandore - Ashford Cancer Centre (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
4215 - Southport - ICON Cancer Care (1)
4350 - Toowoomba - Toowoomba Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
2139 - Concord - Concord Repatriation General Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
NZ.0110 - Whangarei - Whangarei Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
NA
2145 - Westmead - The Children's Hospital at Westmead (1)
4217 - Benowa - Pindara Private Hospital (1)
Cancer Type
Cancer
Gynaecological cancer
Solid tumour
Ovarian cancer
Endometrial cancer
Breast cancer
Thoracic cancer
Gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Upper gastrointestinal cancer
Pancreatobiliary cancer
Non-small cell lung cancer
Urogenital cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Viral-related cancer
Pancreatic cancer
Cervical cancer
Epithelial Ovarian Cancer
Gastroesophageal cancer
Breast adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
Triple-negative breast cancer
Carcinoma
Bladder cancer
Gastric cancer
Head and neck squamous cell carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Male genital cancers
Prostate cancer
Melanoma
Oesophageal cancer
Fallopian tube cancer
Ovarian adenocarcinoma
Hepatobiliary cancer
Ovarian serous carcinoma
Peritoneal cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
High-grade serous ovarian cancer
Clear cell renal cell carcinoma
Kidney cancer
Endometrial carcinoma
Primary peritoneal serous carcinoma
Skin cancer
Hepatocellular carcinoma
Biliary tract cancer
Sarcoma
Platinum resistant ovarian cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Primary fallopian tube serous carcinoma
Non-squamous non-small-cell lung cancer
Mesothelioma
Uterine serous carcinoma
Prostate adenocarcinoma
Pleural mesothelioma
HER2-negative breast cancer
Cutaneous squamous cell carcinoma
Non-melanoma skin cancer
Anal cancer
Central nervous system cancer
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Renal pelvis cancer
Cutaneous melanoma
Endometrial adenocarcinoma
Endometrial endometrioid carcinoma
Castrate-resistant prostate cancer
Low-grade serous ovarian cancer
Uveal melanoma
Lung adenocarcinoma
Adenocarcinoma
Squamous non-small-cell lung cancer
Salivary gland cancer
Endocrine gland cancer
Thyroid cancer
Glioblastoma
Oesophageal squamous cell carcinoma
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
Follicular lymphoma
Haematological malignancy
High-grade B-cell lymphoma
Lymphoma
Mantle cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Carcinosarcoma
Ovarian carcinosarcoma
Uterine carcinosarcoma
Endometrial clear cell carcinoma
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
dMMR solid cancer
Colorectal adenocarcinoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
HER2-positive breast cancer
Anal squamous cell carcinoma
Squamous cell carcinoma
Adenoid cystic carcinoma
Cancer Solid tumour Carcinoma
Cholangiocarcinoma
Gastro-entero-pancreatic neuroendocrine tumour
Lung carcinoid tumour
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland carcinoma
Vaginal and vulvar cancer
Vulval cancer
Endometrial stromal sarcoma
Leiomyosarcoma
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Sex cord-gonadal stromal tumour
Soft tissue sarcoma
Uterine leiomyosarcoma
Differentiated thyroid carcinoma
H3K27M-mutant glioma
Papillary thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy